Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02485015
PHASE2

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Sponsor: The First People's Hospital of Changzhou

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.

Official title: The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2015-06

Completion Date

2033-06

Last Updated

2016-02-19

Healthy Volunteers

No

Interventions

BIOLOGICAL

Cytokine-Induced Killer Cells

Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.

DRUG

Apatinib

Advanced gastric cancer patients take Apatinib 850mg qd by mouth.